Entera Bio Ltd. (ENTX) Reports $15.6M Q3 Net Loss; Cash Expected to Fund Program Through 2030

Entera Bio (ENTX) reported a Q3 2026 net loss of $15.6M, wider than the $3.2M loss a year earlier, including a $7.5M non-cash warrant remeasurement. The company had $265.9M in cash and expects funds to last through 2030, supporting its EB613 program and operations.

Original reporting
Published Nov 6, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Entera Bio Ltd. (ENTX) Reports $15.6M Q3 Net Loss; Cash Expected to Fund Program Through 2030 — source image
Decision brief

The 30-second read

$ENTXBearishMed
01

Why it matters

The earnings miss may depress the stock in the short term, but the sizable cash balance and upcoming trial could mitigate long‑term risk.

02

Market read

First‑time earnings disclosure for a micro‑cap biotech; provides new data for traders.

03

What to watch

Potential upside from upcoming EB613 Phase 3 trial and NDA filing timeline.

Relevance 6/10Novelty 6/10Timing: after-hours

Background

Entera Bio reported its Q3 2026 financial results, highlighting a net loss and cash position while preparing for a Phase 3 trial of EB613.

Company-level read

Ticker impact

$ENTXBearishHigh confidence
Context

Q3 2026 net loss of $15.6M and cash balance of $265.9M disclosed for the first time.

Expected impact

likely pressure as investors price in the larger loss despite ample cash.

Evidence & confidence

Earnings release provides fresh financial metrics; loss magnitude exceeds prior year and market typically reacts negatively to widening losses.

Market effects

Biotech sector may see modest pullback as earnings miss expectations.

US biotech investors may adjust exposure.

Limited; primarily affects Entera and peers.

Counterpoint

Cash runway to 2030 could support upside if Phase 3 data are positive.

Key entities

  • Entera Bio Ltd.

    Biotech firm developing EB613.

Related articles

$ENTXMedAI 8/10

A planned osteoporosis pill trial is expected to enroll about 900 women. Entera expects its first site to open in late 2026.

Entera Bio (ENTX) plans to initiate a Phase 3 trial for its osteoporosis drug EB613 in late 2026, with 900 women expected to enroll. The company presented Phase 2 data at ASBMR 2026, showing potential benefits for patients with low bone mineral density. Entera also announced key leadership appointments and financial results for Q3 2026.

$ENTXMedAI 8/10

Entera Bio to present Phase 3 trial design for oral osteoporosis drug

Entera Bio (ENTX) will present Phase 3 trial design for its oral osteoporosis drug, EB613, at a conference in October 2026. The study will evaluate EB613 in postmenopausal women with osteoporosis. The company previously reported positive Phase 2 results, showing improvements in bone density and markers. EB613 is an oral, once-daily tablet, unlike current anabolic therapies that require injections.

$ENTXMed

Entera Receives $9 Price Target and New 'Outperform' Rating From Leerink Partners (NASDAQ: ENTX)

Entera Bio (ENTX) received an 'Outperform' rating and $9 price target from Leerink Partners. The company's lead drug, EB613, is in development for osteoporosis and has completed Phase 2 trials. Entera recently raised $275M in funding and plans to initiate Phase 3 trials in late 2026, with data expected in 2028. ENTX was trading at $3.03 per share as of September 17, 2026.